| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
|---|---|
| antibiotics, tetracycline | <chemical> Broad-spectrum natural and semisynthetic antibiotics with a naphthacene structure obtained from various streptomyces species. Pharmacological action: protein synthesis inhibitor. (12 Dec 1998) |
| antibiotin | <protein> Biotin binding protein (68 kD) from egg white. Binding is so strong as to be effectively irreversible a diet of raw egg white leads to biotin deficiency. (18 Nov 1997) |
| antiblennorrhagic | Rarely used term for:1. Preventive or curative of a mucous discharge (blennorrhagia). 2. A remedy possessing such properties. (05 Mar 2000) |
| antibodies | Any of numerous protein molecules produced by the B-cells as a primary immune defense. (16 Dec 1997) |
| antibodies, anti-idiotypic | Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. (12 Dec 1998) |
| antibodies, anticardiolipin | Antiphospholipid antibodies found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase immunoassay employing the purified phospholipid antigen cardiolipin. (12 Dec 1998) |
| antibodies, antineutrophil cytoplasmic | Autoantibodies directed against cytoplasmic constituents of polymorphonuclear leukocytes and/or monocytes. They are used as specific markers for wegener's granulomatosis and other diseases, though their pathophysiological role is not clear. Anca are routinely detected by indirect immunofluorescence with three different patterns: c-anca (cytoplasmic), p-anca (perinuclear), and atypical anca. (12 Dec 1998) |
| antibodies, antinuclear | See: Antinuclear antibodies. (12 Dec 1998) |
| antibodies, antiphospholipid | Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals. (12 Dec 1998) |
| antibodies, archaeal | Immunoglobulins induced by substances elaborated by archaea that have an antigenic activity. (12 Dec 1998) |
| antibodies, bacterial | Immunoglobulins induced by substances elaborated by bacteria that have an antigenic activity. (12 Dec 1998) |
| antibodies, bispecific | Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate antigenic determinants. They are artificial antibodies produced by chemical crosslinking, fusion of hybridoma cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabelled haptens, and effector cells to diseased tissue, primarily tumours. (12 Dec 1998) |
| antibodies, blocking | Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies. (12 Dec 1998) |
| antibodies, catalytic | Antibodies that can catalyze a wide variety of chemical reactions. They are characterised by high substrate specificity and share many mechanistic features with enzymes. (12 Dec 1998) |